Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Bloating in Irritable Bowel Syndrome Is Associated with Symptoms Severity, Psychological Factors, and Comorbidities.

Hod K, Ringel Y, van Tilburg MAL, Ringel-Kulka T.

Dig Dis Sci. 2018 Dec 18. doi: 10.1007/s10620-018-5352-5. [Epub ahead of print]

PMID:
30565010
2.

Endoscopic findings and esophageal cancer incidence among Fanconi Anemia patients participating in an endoscopic surveillance program.

Itskoviz D, Tamary H, Krasnov T, Yacobovich J, Sahar N, Zevit N, Shamir R, Ben-Bassat O, Leibovici Wiseman Y, Dickman R, Ringel Y, Dotan I, Goldberg Y, Morgenstern S, Levi Z.

Dig Liver Dis. 2019 Feb;51(2):242-246. doi: 10.1016/j.dld.2018.08.010. Epub 2018 Aug 18.

PMID:
30249500
3.

Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.

Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T.

Dig Dis Sci. 2018 Jul;63(7):1890-1899. doi: 10.1007/s10620-018-5086-4. Epub 2018 May 17.

PMID:
29777439
4.

Microbiome-Based Diagnostics: Ready for Applications in Laboratory Medicine?

Versalovic J, Dore J, Guarner F, Luna RA, Ringel Y.

Clin Chem. 2017 Nov;63(11):1674-1679. doi: 10.1373/clinchem.2016.264473. Epub 2017 Sep 7. No abstract available.

5.

Editorial: Clinical Implications of Diagnosing Irritable Bowel Syndrome: Do All Roads Need to Lead to Rome?

Keszthelyi D, Ringel Y.

Am J Gastroenterol. 2017 Jun;112(6):900-902. doi: 10.1038/ajg.2017.115.

PMID:
28572651
6.

Risk of advanced lesions at the first follow-up colonoscopy after polypectomy of diminutive versus small adenomatous polyps of low-grade dysplasia.

Sneh Arbib O, Zemser V, Leibovici Weissman Y, Gingold-Belfer R, Vilkin A, Eizenstein S, Cohen A, Comaneshter D, Tzipora S, Niv Y, Ringel Y, Lieberman D, Levi Z.

Gastrointest Endosc. 2017 Oct;86(4):713-721.e2. doi: 10.1016/j.gie.2017.02.034. Epub 2017 Mar 8.

PMID:
28284884
7.

The Gut Microbiome in Irritable Bowel Syndrome and Other Functional Bowel Disorders.

Ringel Y.

Gastroenterol Clin North Am. 2017 Mar;46(1):91-101. doi: 10.1016/j.gtc.2016.09.014. Review.

PMID:
28164856
8.
9.

Use of probiotics in prevention and treatment of patients with Clostridium difficile infection.

Ollech JE, Shen NT, Crawford CV, Ringel Y.

Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):111-8. doi: 10.1016/j.bpg.2016.01.002. Epub 2016 Jan 14. Review.

PMID:
27048902
10.

Probiotics in functional bowel disorders.

Hod K, Ringel Y.

Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):89-97. doi: 10.1016/j.bpg.2016.01.003. Epub 2016 Jan 14. Review.

PMID:
27048900
11.

Preface.

Dieleman LL, Ringel YU.

Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):1-2. doi: 10.1016/j.bpg.2016.02.012. Epub 2016 Mar 3. No abstract available.

PMID:
27048891
12.

Response to Valeur et al. and Farmer et al.

Choi CH, Ringel-Kulka T, Ringel Y.

Am J Gastroenterol. 2016 Jan;111(1):147-8. doi: 10.1038/ajg.2015.409. No abstract available.

PMID:
26785665
13.

Molecular characterization of the intestinal microbiota in patients with and without abdominal bloating.

Ringel-Kulka T, Benson AK, Carroll IM, Kim J, Legge RM, Ringel Y.

Am J Physiol Gastrointest Liver Physiol. 2016 Mar 15;310(6):G417-26. doi: 10.1152/ajpgi.00044.2015. Epub 2015 Dec 23.

14.

Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion.

Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA, Qamar AA, Miloh TA, Guarino A, Guslandi M, Dieleman LA, Ringel Y, Quigley EM, Brandt LJ.

J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S69-73. doi: 10.1097/MCG.0000000000000420. Erratum in: J Clin Gastroenterol. 2016 Oct;50(9):800.

PMID:
26447969
15.

The Intestinal Microbiota and Irritable Bowel Syndrome.

Ringel Y, Ringel-Kulka T.

J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S56-9. doi: 10.1097/MCG.0000000000000418.

PMID:
26447966
16.

Discordant temporal development of bacterial phyla and the emergence of core in the fecal microbiota of young children.

Cheng J, Ringel-Kulka T, Heikamp-de Jong I, Ringel Y, Carroll I, de Vos WM, Salojärvi J, Satokari R.

ISME J. 2016 Apr;10(4):1002-14. doi: 10.1038/ismej.2015.177. Epub 2015 Oct 2.

17.

Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome.

Ringel-Kulka T, Choi CH, Temas D, Kim A, Maier DM, Scott K, Galanko JA, Ringel Y.

Am J Gastroenterol. 2015 Sep;110(9):1339-46. doi: 10.1038/ajg.2015.220. Epub 2015 Aug 25.

18.

Testing in Microbiome-Profiling Studies with MiRKAT, the Microbiome Regression-Based Kernel Association Test.

Zhao N, Chen J, Carroll IM, Ringel-Kulka T, Epstein MP, Zhou H, Zhou JJ, Ringel Y, Li H, Wu MC.

Am J Hum Genet. 2015 May 7;96(5):797-807. doi: 10.1016/j.ajhg.2015.04.003.

19.

High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome.

Hod K, Ringel-Kulka T, Martin CF, Maharshak N, Ringel Y.

J Clin Gastroenterol. 2016 Mar;50(3):227-32. doi: 10.1097/MCG.0000000000000327.

20.

High throughput sequencing reveals distinct microbial populations within the mucosal and luminal niches in healthy individuals.

Ringel Y, Maharshak N, Ringel-Kulka T, Wolber EA, Sartor RB, Carroll IM.

Gut Microbes. 2015;6(3):173-81. doi: 10.1080/19490976.2015.1044711.

21.

Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study.

Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, Palsson O, Jobin C, Ringel Y.

Aliment Pharmacol Ther. 2014 Jul;40(2):200-7. doi: 10.1111/apt.12800. Epub 2014 May 22.

22.

Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial.

van Tilburg MA, Palsson OS, Ringel Y, Whitehead WE.

Complement Ther Med. 2014 Feb;22(1):17-20. doi: 10.1016/j.ctim.2013.12.015. Epub 2014 Jan 8.

23.

Fecal protease activity is associated with compositional alterations in the intestinal microbiota.

Carroll IM, Ringel-Kulka T, Ferrier L, Wu MC, Siddle JP, Bueno L, Ringel Y.

PLoS One. 2013 Oct 17;8(10):e78017. doi: 10.1371/journal.pone.0078017. eCollection 2013.

24.

Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.

Ringel Y, Maharshak N.

Am J Physiol Gastrointest Liver Physiol. 2013 Oct 15;305(8):G529-41. doi: 10.1152/ajpgi.00207.2012. Epub 2013 Jul 25. Review.

25.

Intestinal microbiota in healthy U.S. young children and adults--a high throughput microarray analysis.

Ringel-Kulka T, Cheng J, Ringel Y, Salojärvi J, Carroll I, Palva A, de Vos WM, Satokari R.

PLoS One. 2013 May 23;8(5):e64315. doi: 10.1371/journal.pone.0064315. Print 2013.

26.

Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS.

Annaházi A, Ferrier L, Bézirard V, Lévêque M, Eutamène H, Ait-Belgnaoui A, Coëffier M, Ducrotté P, Róka R, Inczefi O, Gecse K, Rosztóczy A, Molnár T, Ringel-Kulka T, Ringel Y, Piche T, Theodorou V, Wittmann T, Bueno L.

Am J Gastroenterol. 2013 Aug;108(8):1322-31. doi: 10.1038/ajg.2013.152. Epub 2013 May 28.

PMID:
23711626
27.

The intestinal microbiome, probiotics and prebiotics in neurogastroenterology.

Saulnier DM, Ringel Y, Heyman MB, Foster JA, Bercik P, Shulman RJ, Versalovic J, Verdu EF, Dinan TG, Hecht G, Guarner F.

Gut Microbes. 2013 Jan-Feb;4(1):17-27. doi: 10.4161/gmic.22973. Epub 2012 Nov 30. Review.

28.

Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications.

Bäckhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, Versalovic J, Young V, Finlay BB.

Cell Host Microbe. 2012 Nov 15;12(5):611-22. doi: 10.1016/j.chom.2012.10.012.

29.

Characterization of the fecal microbiota using high-throughput sequencing reveals a stable microbial community during storage.

Carroll IM, Ringel-Kulka T, Siddle JP, Klaenhammer TR, Ringel Y.

PLoS One. 2012;7(10):e46953. doi: 10.1371/journal.pone.0046953. Epub 2012 Oct 5.

30.

Burden of gastrointestinal disease in the United States: 2012 update.

Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, DiBonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ.

Gastroenterology. 2012 Nov;143(5):1179-1187.e3. doi: 10.1053/j.gastro.2012.08.002. Epub 2012 Aug 8.

31.

Prebiotics and the health benefits of fiber: current regulatory status, future research, and goals.

Brownawell AM, Caers W, Gibson GR, Kendall CW, Lewis KD, Ringel Y, Slavin JL.

J Nutr. 2012 May;142(5):962-74. doi: 10.3945/jn.112.158147. Epub 2012 Mar 28.

PMID:
22457389
32.

Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.

Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y.

Neurogastroenterol Motil. 2012 Jun;24(6):521-30, e248. doi: 10.1111/j.1365-2982.2012.01891.x. Epub 2012 Feb 20.

33.

Anti-enteric neuronal antibodies and the irritable bowel syndrome.

Wood JD, Liu S, Drossman DA, Ringel Y, Whitehead WE.

J Neurogastroenterol Motil. 2012 Jan;18(1):78-85. doi: 10.5056/jnm.2012.18.1.78. Epub 2012 Jan 16.

34.

Recommendations for probiotic use-2011 update.

Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, Dieleman LA, Ringel Y, Guandalini S, Kelly CP, Brandt LJ.

J Clin Gastroenterol. 2011 Nov;45 Suppl:S168-71. doi: 10.1097/MCG.0b013e318230928b.

PMID:
21992958
35.

The rationale and clinical effectiveness of probiotics in irritable bowel syndrome.

Ringel Y, Ringel-Kulka T.

J Clin Gastroenterol. 2011 Nov;45 Suppl:S145-8. doi: 10.1097/MCG.0b013e31822d32d3. Review.

PMID:
21992954
36.

Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.

Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, Ringel Y.

Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G799-807. doi: 10.1152/ajpgi.00154.2011. Epub 2011 Jul 7.

37.

Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study.

Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G, Ringel Y.

J Clin Gastroenterol. 2011 Jul;45(6):518-25. doi: 10.1097/MCG.0b013e31820ca4d6.

38.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group.

N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.

39.

Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.

Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y.

Gut Pathog. 2010 Dec 9;2(1):19. doi: 10.1186/1757-4749-2-19.

40.

Drug Class Review: Constipation Drugs: Final Report [Internet].

Gartlehner G, Jonas DE, Morgan LC, Ringel Y, Hansen RA, Bryant CM, Carey T.

Portland (OR): Oregon Health & Science University; 2007 Sep.

41.

Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation.

Camilleri M, Thorne NK, Ringel Y, Hasler WL, Kuo B, Esfandyari T, Gupta A, Scott SM, McCallum RW, Parkman HP, Soffer E, Wilding GE, Semler JR, Rao SS.

Neurogastroenterol Motil. 2010 Aug;22(8):874-82, e233. doi: 10.1111/j.1365-2982.2010.01517.x. Epub 2010 May 11.

42.

Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence.

Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE.

Dis Colon Rectum. 2009 Oct;52(10):1730-7. doi: 10.1007/DCR.0b013e3181b55455.

43.

Alterations in the intestinal microbiota and functional bowel symptoms.

Ringel Y, Carroll IM.

Gastrointest Endosc Clin N Am. 2009 Jan;19(1):141-50, vii. doi: 10.1016/j.giec.2008.12.004. Review.

PMID:
19232285
44.

Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome.

Ringel Y, Williams RE, Kalilani L, Cook SF.

Clin Gastroenterol Hepatol. 2009 Jan;7(1):68-72; quiz 3. doi: 10.1016/j.cgh.2008.07.008.

PMID:
19124113
45.

Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study.

Ringel Y, Drossman DA, Leserman JL, Suyenobu BY, Wilber K, Lin W, Whitehead WE, Naliboff BD, Berman S, Mayer EA.

Gastroenterology. 2008 Feb;134(2):396-404. doi: 10.1053/j.gastro.2007.11.011. Epub 2007 Nov 12.

PMID:
18242208
46.

Lubiprostone: easing the strain of constipation?

Dorn SD, Ringel Y.

Gastroenterology. 2008 Jan;134(1):355-7. doi: 10.1053/j.gastro.2007.11.051. No abstract available.

PMID:
18166366
47.

Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity.

Dorn SD, Palsson OS, Thiwan SI, Kanazawa M, Clark WC, van Tilburg MA, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell MD, Olden KW, Whitehead WE.

Gut. 2007 Sep;56(9):1202-9. Epub 2007 May 4.

48.

Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation.

Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE.

Dis Colon Rectum. 2007 Apr;50(4):428-41.

PMID:
17294322
49.

Probiotics in irritable bowel syndrome: has the time arrived?

Ringel-Kulka T, Ringel Y.

Gastroenterology. 2007 Feb;132(2):813-6; discussion 816. No abstract available.

PMID:
17261299
50.

Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study.

Kariv R, Tiomny E, Grenshpon R, Dekel R, Waisman G, Ringel Y, Halpern Z.

Dig Dis Sci. 2006 Dec;51(12):2128-33. Epub 2006 Nov 1.

PMID:
17080248

Supplemental Content

Loading ...
Support Center